Tango Therapeutics (TNGX) Q3 2025 shows a major financial inflection point driven by a one-time collaboration event. The company reported Net Income of $15.9M for Q3 2025, reversing a $29.2M loss year-over-year. This profitability resulted from the truncation of the Gilead collaboration research term, leading to the immediate recognition of $53.8M in previously deferred revenue, eliminating remaining research obligations under that deal.
For the nine months ended September 30, 2025, the Net Loss narrowed substantially to ($62.8M) from ($92.6M) in 2024. Revenue for the quarter
...